It is further theorized that hypomethylating agents such as 5-azacytidine would be effective in TET2-mutated cancers given the significantly increased efficacy of 5-azacytidine in TET2 mutant subgroups in the treatment of myelodysplastic syndrome (164). Here, TET2 is linked to myelodysplastic syndrome.